



## Ocular Manifestations and Socio-Demographic Factors among Adults on Highly Active Antiretroviral Therapy (HAART) in Enugu, Nigeria

Amalachukwu Amanda Chime <sup>a</sup>, Ugochukwu Anthony Eze <sup>b\*</sup>,  
Stella Ngozi Onwubiko <sup>a</sup>, Nnenma Ndidiamaka Udeh <sup>a</sup>,  
Michael Okwudili Chime <sup>c</sup>, Michael O. Olaolu <sup>d</sup>, Onochie Ike Okoye <sup>a</sup>,  
Ernest Nnaemeka Onwasigwe <sup>a</sup> and Rich Enujoike Umeh <sup>a</sup>

<sup>a</sup> Ophthalmology Department, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria.

<sup>b</sup> Department of Ophthalmology, Federal Medical Centre, Asaba, Nigeria.

<sup>c</sup> Anaesthesia Department, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria.

<sup>d</sup> Department of Agriculture, Alex Ekwueme University, Ndufu Alike, Nigeria.

### Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

### Article Information

DOI: 10.9734/JAMMR/2022/v34i224827

### Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/92431>

Original Research Article

Received 08 July 2022  
Accepted 11 October 2022  
Published 15 October 2022

### ABSTRACT

HIV/AIDS is associated with systemic immune dysfunction which makes the body susceptible to certain opportunistic infections and tumours. The advent of HAART has now provided some desired improvement leading to altered patterns of clinical findings which include ocular manifestations.

**Objective:** To determine the socio-demographic association, frequency and types of ocular manifestations of HIV/AIDS in adult HIV positive patients in Enugu.

**Methods:** This was a hospital-based cross-sectional descriptive study. It comprised 331 randomly selected and consenting adult HIV positive patients on Highly Active Anti-Retroviral Therapy (HAART) at the retroviral disease clinic of UNTH Enugu, Nigeria. They had slit lamp examination of the anterior and posterior segment. Data was obtained using an interviewer administered semi-structured questionnaire. Data analysis was with SPSS version 21. Their demographic data,

frequency and pattern of ocular manifestations were presented in frequency and percentages. A p-value of < 0.05 was used to define statistical significance at 95% confidence interval.

**Results:** The hospital prevalence of HIV related ocular manifestations was 18.4%. HIV microangiopathy was the commonest (18.8%). Posterior segment ocular manifestations were the commonest (37.7%) observed class of HIV ocular manifestations. Of those with HIV related ocular manifestations, only 33.3% had a previous history of eye problem. There was no statistically significant association between the socio-demographic variables and the ocular findings.

**Conclusion:** Pharmacotherapy has altered the overall clinical course of HIV/AIDS. However, HIV related ocular manifestations are still common, though no association was found between the demographic variables of the population and the ocular findings. We recommend that all patients on follow up in for HIV/AIDS should continue to adhere strictly to recommended HAART regimen.

*Keywords: Ocular manifestations; HIV/AIDS; Enugu Nigeria; HAART.*

## 1. INTRODUCTION

Acquired immunodeficiency syndrome (AIDS) is a multisystem disease characterized by decreased body immunity with the onset of a number of opportunistic infections and tumors [1,2]. The etiology is human immunodeficiency virus (HIV), a retrovirus with elective tropism for the T-helper lymphocytes (CD4+) transmitted through blood and bodily fluids [1,2] via unsafe sex, parenteral route, and perinatal route [3,4]. Since the first case of acquired immunodeficiency syndrome (AIDS) was diagnosed in 1981, the cases of human immunodeficiency virus (HIV) infection have been increasing worldwide [5,6]. The first cases of HIV/AIDS in Nigeria were reported in Lagos and Enugu in 1986 among commercial sex workers [7]. The ocular manifestations of HIV/AIDS, first reported by Holland et al, [8] may be the primary presentation of the disease [9,10] and can range from a simple blepharitis to blindness [11].

These ocular manifestations can be classified pathologically or anatomically [12,13]. Pathologically, the categories include non - infectious retinopathy, opportunistic infections, unusual neoplasm and neuro-ophthalmic manifestations. Anatomically, the categories include orbital manifestations, adnexal manifestations, anterior segment manifestations, posterior segment manifestations and neuro – ophthalmic manifestations.

The spectrum and prevalence of ocular diseases in HIV-infected patients in developing countries differ from those in developed countries where most of the studies have been done [14,15]. Cytomegalovirus retinitis seems to be more prevalent in the developed countries, unlike in developing countries where herpes zoster

ophthalmicus is more prevalent [16]. This study hopes to show the pattern in our location and this will be compared to what is known in previous literature.

The pattern of ocular manifestations also varies between the pre- HAART and HAART era. In the pre HAART era, the major battle was with opportunistic ocular infections, however with the introduction of HAART, conditions such as immune recovery uveitis (IRU) emerged [17,18]. This study is aimed at determining the ocular manifestations of HIV/AIDS and associated socioeconomic factors in Adults on HAART in Enugu state with a view to providing a database and making recommendations for improved ocular health for these patients.

## 2. MATERIALS AND METHODS

This was a descriptive cross-sectional study of HIV positive adults on HAART in Enugu state which is one of the 36 States of Nigeria. It is bounded on the north by Kogi and Benue States, on the east by Ebonyi State, on the west by Anambra State and on the south by Abia State. During the data collection period, about 120 to 150 patients were seen daily at the antiretroviral therapy (ART) clinic of the University of Nigeria Teaching Hospital, Enugu, which was the point of data collection. A systematic random sampling technique was used to select the participants. A total of 331 participants responded.

The sample size was calculated using the formula

$$n = \frac{z^2 Pq}{d^2}$$

where n= minimum sample size, z= confidence limits of survey results; 95% (Z=1.96), P= proportion of target population with the

characteristics,  $q = 1 - P$ ,  $d =$  precision; 5% Using a hospital prevalence of HIV ocular manifestation of 26.3%, [19] the minimum sample size was:

$$\frac{(1.96)^2 \times 0.263 \times 0.737}{(0.05)^2}$$

=297.7 = 298. Correcting for an attrition rate of 10% = 29.8, the minimum sample size was 328; however, 331 participants were recruited for the study.

Consenting adult ( $\geq 18$  years) HIV positive patients were included in the study. Patients who due to impaired mental and/or physical state could not be examined or were pregnant were excluded. Anterior and posterior segment examinations were conducted using ophthalmic equipment/accessories such as slit lamp biomicroscope, +90D lens. Pretested semi-structured interviewer based questionnaires were used for data collection. Information obtained from the interview (such as bio-data, duration on HAART, regimen) and the clinical examination were recorded in the questionnaire. The examinations conducted include visual acuity, pen torch external eye examination, slit lamp adnexal, anterior and posterior segment examination.

The demographic data of the participants, frequency and pattern of ocular manifestations were recorded and presented in frequency and percentages. Data analysis was with Statistical Package for Social Sciences (SPSS) version 21. Chi square and Fisher's Exact test was used to test for association and a  $p$  value of  $< 0.05$  was considered significant.

### 3. RESULTS

Out of 331 patients who participated in the study, 252 (76.1%) were females. The male to female ratio was 1: 3.2. Participants were aged between 22 and 81 years with a mean of  $43.6 \pm 9.9$  years. A total of 61 participants (18.4%) had ocular manifestation.

The mean CD4+ cell count of the study participants was  $575.0 \pm 512.56$  cells/ $\mu$ l, while that of those with ocular manifestations was  $315.2 \pm 290.76$  cells/ $\mu$ l.

Table 1 shows the relationship between socio-demographic factors and ocular manifestations of HIV. The mean age of those with ocular manifestations was  $45.0 \pm 11.6$  years. A majority

(80.3%) of those with ocular manifestations were within the age range of 25–54 years. Females constituted 41 (67.2%) of those with ocular manifestations and most (30) of whom were married (49.2%). There was no statistically significant difference between these factors and the ocular findings.

Blurred vision, difficulty with near work and itching were the most common presenting complaints (Fig. 1) Also, participants noted to be blind had presenting visual acuity  $\leq 3/60$  i.e. 1.30LogMAR. None had severe visual impairment (presenting visual acuity  $\leq 6/60 \geq 3/60$  i.e. 1.01 – 1.30LogMAR). The prevalence of visual impairment (VI) and blindness of 19.7% and 4.9% respectively was observed. (Fig. 2) Of the 3 (4.9%) noted to be blind, 2 had optic atrophy while the other had CMVR.

The most common diagnosis among the participants were HIV microangiopathy (18.8%), conjunctival microvasculopathy and keratoconjunctivitis sicca (14.5%). The most common class of ocular manifestation was posterior segment ocular manifestation (37.7%) while the least was neuro ophthalmic (10.1%). Most of the participants (97.9%) had an ocular symptom at time of interview and a few (32.6%) had previous history of ocular symptoms prior to HIV diagnosis. All those without any current ocular symptoms also had no HIV related ocular manifestation. However, there was no statistically significant association between reported symptoms and HIV related ocular manifestations ( $p > 0.05$ ).

### 4. DISCUSSION

The prevalence of ocular manifestation in this study was low compared with the report of other studies [19–22]. This low prevalence of ocular manifestations may be due to the fact that all the participants recruited were on HAART and most (63.1%) had been on HAART for more than 5 years. Higher prevalence reported by some researchers [20–23] was attributed to most of the patients being at WHO clinical stages III and IV, [21,22] as well as having low CD4+ cell count of less than 200 cells/ $\mu$ l [22]. Though these clinical parameters were not reported in this particular report, which is part of a larger study which also reported a wide range of systemic clinical/ laboratory parameter, [24] compared to what was earlier reported in Ethiopia and Tanzania by Assefa et al and Sahoo respectively [21,22]. Other researchers have on the other hand noted lower

prevalence of ocular manifestation, which was attributed to good medication coverage [2,24]. A study in Brazil reported that no ocular manifestation of HIV was noted among the study participants and this was attributed to small sample size (42 participants) and the fact that all but one of those studied were on HAART [25]. However the sample size difference could have accounted for the different observations in our population and theirs.

Blurred vision and difficulty reading were the most prevalent presenting symptoms. This is not surprising, considering the mean age of the study population who are within the presbyopic

range and the fact that about 1/5<sup>th</sup> of the participants had some degree of visual impairment. This is much lower than a report by Adeniyi in Markudi, Nigeria which reported a prevalence of 15% and 45% for blindness and visual impairment respectively [5]. An adducible reason to this was the fact the majority were yet to commence HAART unlike this study where all respondents were on therapy with about 2/3<sup>rd</sup> of the study population on HAART for about 5years. Also, blurring of vision was the most common symptom as shown in Adeniyi's report, however over 30% of the population in the study were less than 30 years [5].

**Table 1. Relationship between socio-demographic factors and HIV Related Ocular Manifestations (HROM) (N=331)**

Socio demographics		Manifestation of HROM		Chi-square trend test (Linear by linear test)	P-value
		Absent	Present		
Age	< 25	2(0.7)	0(0.0)	0.637	0.524
	25-34	37(13.7)	7(11.5)		
	35-44	125(46.3)	24(39.3)		
	45-54	78(28.9)	18(29.5)		
	55-64	19 (7.0)	5(8.2)		
	≥65	9(3.3)	7(11.5)		
Educational Status	None	9 (3.3)	5(8.2)	0.57	0.620
	Primary	73(27.0)	16(26.2)		
	Secondary	106(39.3)	20 (32.8)		
	Tertiary	82 (30.4)	20 (32.8)		
				<b>Chi-square / Fisher's Exact</b>	<b>P-value</b>
Sex	Male	59 (21.9)	20 (32.8)	3.3	0.071
	Female	211 (78.1)	41(67.2)		
Marital Status	Single	50 (18.5)	13(21.3)	1.6	0.801
	Married	122(45.2)	30 (49.2)		
	Divorced	8(3.0)	2(3.3)		
	Separated	3(1.1)	0(0.0)		
	Widowed	87 (32.2)	16(26.2)		
Occupation	Civil Servant	62(23.0)	14(23.0)	12.8	0.234
	Trader	95(35.2)	20(32.3)		
	farmer/Agricultural worker	29 (10.7)	8(13.1)		
	Artisan	35 (13.0)	14 (23.0)		
	Unemployed	32(11.9)	3(4.9)		
	Driver/ cyclist	4(1.5)	0(0.0)		
	Military/ Paramilitary	2(0.7)	0 (0.0)		
	Health worker	3(1.1)	0(0.0)		
	Self employed	7(2.6)	1(1.6)		
	Clergy	1(0.4)	0(0.0)		
	Student	0(0.0)	1(1.6)		




Fig. 1. Chart showing current ocular complaint/ symptoms among participants at time of review




Fig. 2. Visual status of 61 participants with ocular manifestations. (Key VI = Visual impairment)

Table 2. Frequency of ocular manifestations of HIV among the participants

HIV Related Ocular Manifestations	Frequency	Percentage
<b>Adnexal Manifestations</b>		
Conjunctival microvasculopathy	10	14.5
Active Herpes zoster ophthalmicus	4	5.8
Squamous cell carcinoma	3	4.4
Molluscum contagiosum	1	1.5
<b>Anterior Segment Manifestations</b>		
Keratoconjunctivitis sicca	10	14.5
Anterior Uveitis	6	8.7
Keratitis	2	2.9

HIV Related Ocular Manifestations	Frequency	Percentage
<b>Posterior Segment Manifestations</b>		
HIV microangiopathy	13	18.8
Immune recovery uveitis	6	8.7
Toxoplasma retinitis	4	5.8
Cytomegalovirus retinitis	3	4.4
<b>Neuro-ophthalmic Manifestations</b>		
Optic atrophy	3	4.4
Gaze palsy	2	2.9
Pupillary abnormality	2	2.9

**Table 3. Showing classes of ocular manifestations of HIV among participants**

Types of HIV Related Ocular Manifestations	Frequency	Percentage (%)
Adnexal	18	26.1
Ant. segment	18	26.1
Post segment	26	37.7
Neurophthalmic	7	10.1
Orbital	0	0.0

Listo et al. [26] in their study reported that about 26% and 26.5% of the HIV related ocular manifestations, were found in the adnexa and anterior segment respectively. This may be attributed to more than half of their study participants being on HAART and at earlier stages of the disease (stages I and II). However, Bekele et al. [27] in another report showed that adnexal manifestations constituted only 12.8% while 12.3% were in the anterior segment. This difference may be because a majority of their study participants were not on HAART compared to ours who were all on therapy. Anterior segment ocular manifestations are said to occur at a higher CD4+ cell level compared with posterior segment manifestations [10,28]. Conjunctival microvasculopathy was observed as the commonest adnexal presentation in this study. This agrees with existing literature where it was reported in about 80% of presentations [29]. However, studies in Nigeria have shown herpes zoster ophthalmicus to be a common presentation among HIV positive patients sometimes preceding the diagnosis of HIV/AIDS [30,31]. Also in keeping suggestions by Feroze and Wang above [29].

Posterior segment manifestations were the most common class of ocular manifestation reported in this study and this is consistent with earlier reports Makurdi and Nepal [5,32]. Posterior segment manifestations are said to occur more in patients with CD4+ cell level lower than 200cells/ $\mu$ l especially when not on HAART [10,28]. In this study however, all the participants were on HAART and most had CD4 count > 200

cells/ $\mu$ l (The mean CD4+ cell count of the study participants was  $575.0 \pm 512.56$  cells/ $\mu$ l) [33]. Similar to the proposal by other researchers, [27,33] HAART is commenced at lower levels of CD4+ count and the patients possibly could have developed the ocular manifestations before the commencement of HAART; also the newly reconstituted CD4+ cells may not be associated with the functional maturity to offer the required protection to the patients. These observations may explain the higher prevalence of posterior segment manifestations with seemingly high CD4+ cell levels in this study. HIV microangiopathy has been noted to occur more at later stages of HIV infection [6]. This may account for the lower prevalence of HIV microangiopathy reported in this study compared to the study by Azonobi et al. [34] since most of the patients in their study were at later stage of HIV infection compared to the participants in this study.

With the advent of HAART, a new entity, immune reconstitution inflammatory syndrome, part of which is immune recovery uveitis, has been introduced into the spectrum of ocular features associated with HIV/AIDS. Sudharshan et al. [23] observed that 17.4% of those with HIV related ocular manifestations had immune recovery uveitis and 36.2% had cytomegalovirus retinitis; these are higher than the findings of this study. Gogri et al. [10] observed that only 5% of those with HIV related ocular manifestations had immune recovery uveitis and 12.5% had cytomegalovirus retinitis. The prevalence of cytomegalovirus retinitis observed in this study

falls within the range (0.2% to 4.8%) reported by other researchers in Nigeria [35–37]. Immune recovery uveitis, though mainly associated with cytomegalovirus retinitis has been documented to occur in association with other opportunistic infections [23].

Previous studies have reported neuro-ophthalmic features as a rare manifestation of HIV/AIDS [18,21,22,38]. The 10.2% obtained from those study though the least among the different groups of ocular manifestations, it is not a negligible proportion. The orbit has been documented to be rarely involved in HIV disease [32]. Studies by other researchers also show that no orbital manifestation was observed just like was observed in this study [11,39].

Omolase et al. [40] in Nigeria also noted that 12.5% of their participants had a history of eye problems.

This study appears to have the largest sample size among studies in the region, this is a potential source of strength. However, the study protocol did not permit assessment of ocular manifestations in pre-HAART patients. It would have been nice to have such comparisons in a single study.

## 5. CONCLUSION

The frequency of HROM in this population was comparatively low with a 1:2 M: F ratio. There was also no statistical association with any socio-demographic variable. The clinical profile (stage of disease, CD4<sup>+</sup> count) and use of HAART were important factors noted in this study. As part of comprehensive care, it is necessary to ensure that PLWHA get ophthalmic examinations irrespective of their demographic and HAART status. To achieve this, it is important to integrate eye care services into the existing retroviral disease care.

## CONSENT

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

## ETHICAL APPROVAL

The tenets of the Helsinki declaration and the National code of Health research ethics of Nigeria were adhered to and ethical approval was obtained from Health Research Ethics

Committee (HREC) of the University of Nigeria Teaching Hospital, (UNTH) Ituku-Ozalla, Enugu, Nigeria, before the commencement of the study.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Loo AVP, Sujaya S, Peyman M, Florence S, Subrayan V. Retinal manifestations of patients with human immunodeficiency virus, a multiethnic study in Malaysia. *Int J Ophthalmol.* 2011;4(6):641-3. DOI: 10.3980/j.issn.2222-3959.2011.06.13, PMID 22553736.
2. Rutayisire DL, Saiba SE. Ocular manifestations related to HIV / AIDS at Kigali University Teaching Hospital. *Rwanda Med J.* 2010;68(4):47-51.
3. Purushottam J, Thakur AK, Choudhary M, Sharma S, Shah DN. Ocular manifestations in HIV positive and AIDS patients in Nepal. *Int J Clin Med.* 2012; 03(1):14-21. DOI: 10.4236/ijcm.2012.31003.
4. Alam M, Akbar S, Khan A, Aqbal M. Ocular manifestations in HIV positive patients attending Khyber Teaching Hospital Peshawar. *SAARC J Tuberc Lung Dis HIV/AIDS.* 2011;8(2):31-6. DOI: 10.3126/saarctb.v8i2.5899.
5. Adeniyi OS. Ocular manifestations of HIV infection/AIDS in Makurdi- Nigeria. *Afr J Med Sci.* 2011;4(1):1-10.
6. Cunningham ET, Margolis TP. Ocular manifestations of HIV infection. *N Engl J Med.* 1998;339(4):236-44. DOI: 10.1056/NEJM199807233390406, PMID 9673303.
7. Kehinde AV, Samaila E, Eni RN. Ocular aids: experience at the Guinness ophthalmic unit, Kaduna, Nigeria. *Niger J Surg Res.* 2005;7(3):305-8. DOI: 10.4314/njsr.v7i3.12304.
8. Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. Acquired immune deficiency syndrome. Ocular manifestations. *Ophthalmology.* 1983; 90(8):859-73. DOI: 10.1016/s0161-6420(83)80009-8, PMID 6314219.
9. Sahu DK, Namperumalsamy P, Walimbe P, Rajalakshmi C. Ocular manifestations of HIV infection/AIDS in South Indian

- patients. *Indian J Ophthalmol.* 1999; 47(2):79-85.
10. Gogri PY, Misra SL, Kothari RN, Bhandari AJ, Gidwani HV. Ophthalmic manifestations of HIV patients in a rural area of western Maharashtra, India. *Int Sch Res Notices.* 2014;2014:347638. DOI: 10.1155/2014/347638, PMID 27355047.
  11. Acharya PK, Venugopal KC, Karimsab DPBS, Balasubramanya S. Ocular manifestations in patients with HIV infection/AIDS who were referred from the ART centre, Hassan, Karnataka, India. *J Clin Diagn Res.* 2012;6(10):1756-60. DOI: 10.7860/JCDR/2012/4738.2637, PMID 23373045.
  12. Bhatia RS. Ophthalmic manifestations of AIDS. *JACM.* 2002;3(1):85-8.
  13. Govender P, Hansraj R, Visser L. Ocular manifestations of HIV / AIDS: A literature review (Part 1). *S Afr Optom.* 2010; 69(4):193-9.
  14. Lewallen S, HIV/AIDS. What is the impact on prevention of blindness programmes? *Community Eye Heal J.* 2003;16(47):33-4.
  15. Emina MO, Odjimogho SE. Ocular problems in HIV and AIDS patients in Nigeria. *Optom Vis Sci.* 2010;87(12): 979-84. DOI: 10.1097/OPX.0b013e3181fef198, PMID 21099441.
  16. Lewallen S, Kumwenda J, Maher D, Harries AD. Retinal findings in Malawian patients with AIDS. *Br J Ophthalmol.* 1994; 78(10):757-9. DOI: 10.1136/bjo.78.10.757, PMID 7803351.
  17. Heiden D, Holland GN, Jabs DA, Thorne JE. HIV and the eye. *Eyenet.* 2014:37-41.
  18. Amare B, Admassu F, Assefa Y, Moges B, Ali J, Kassu A. Pattern of ocular manifestation of HIV/ AIDS among patients on HAART in ART clinic of Gondar University Hospital, Northwest, Ethiopia. *J Clin Exp Ophthalmol.* 2011;02(11):1-5.
  19. Uzozie CC. Ocular problem of HIV/AIDS patients on HAART at the antiretroviral clinic Nnamdi Azikiwe University Teaching Hospita. 2013;I Nnewi, Nigeria. A dissertation submitted to National Postgraduate Medical College of Nigeria for the award of FMCOpH.
  20. Arruda RF, Muccioli CBJR. Ophthalmological findings in HIV-infected in the post-HAART era and comparison with the number of patients evaluated in the pre-HAART period. *J Braz Med Assoc.* 2004;50(2):1-10.
  21. Assefa Y, Yohannes AG, Melese A. Ocular Manifestations of HIV / AIDS patients in Gondar University Hospital, north west Ethiopia. *Ethiop J Health Dev.* 2006; 20(3):166-9.
  22. Sahoo S. HIV- and AIDS-related ocular manifestations in Tanzanian patients. *Malays J Med Sci.* 2010;17(1):12-6. PMID 22135520.
  23. Sudharshan S, Kaleemunnisha S, Banu AA, Shrikrishna S, George AE, Babu BR, et al. Ocular lesions in 1, 000 consecutive HIV-positive patients in India: a long-term study. *J Ophthal Inflam Infect.* 2013;3(1):2. DOI: 10.1186/1869-5760-3-2, PMID 23514612.
  24. Abdollahi A, Heidari-Bateni G, Zarei R, Kheirandish P, Malekmadani M, Mohraz M, et al. Clinical spectrum of 15 patients with HIV-related ocular involvement in Tehran. *Int J Ophthalmol.* 2010;3(4):331-6. DOI: 10.3980/j.issn.2222-3959.2010.04.13, PMID 22553586.
  25. Vargas MA, Rao LV, M, Castro Figueiredo JF, Souza NV. Ophthalmological conditions of patients with acquired immunodeficiency syndrome with long follow up time. *J Braz Med Assoc.* 2006:1-10.
  26. Listo B, Kollmann K, Kimani K, CO. Ocular manifestations of HIV/AIDS at Moi Teaching and Referral Hospital (AMPATH Clinic). *East Afr J Ophthalmol.* 2009:27-34.
  27. Bekele S, Gelaw Y, Tessema F. Ocular manifestation of HIV/AIDS and correlation with CD4+ cells count among adult HIV/AIDS patients in Jimma town, Ethiopia: a cross sectional study. *BMC Ophthalmol.* 2013;13(20):20. DOI: 10.1186/1471-2415-13-20, PMID 23710936.
  28. Kim YS, Sun HJ, Kim TH, Kang KD, Lee SJ. Ocular manifestations of acquired immunodeficiency syndrome. *Korean J Ophthalmol.* 2015;29(4):241-8. DOI: 10.3341/kjo.2015.29.4.241, PMID 26240508.
  29. Feroze KB, Wang J. Ocular manifestations of HIVIn: *StatPearls* [internet]. Treasure Island, (FL): StatPearls Publishing; 2021.
  30. Nwosu NN. HIV/AIDS in ophthalmic patients: the Guinness Eye Centre Onitsha experience. *Niger Postgrad Med J.* 2008; 15(1):24-7. PMID 18408779.



31. Umeh RE. Herpes zoster ophthalmicus and HIV infection in Nigeria. *Int J STD AIDS*. 1998;9(8):476-9. DOI: 10.1258/0956462981922656, PMID 9702597.
32. Duane TD, Tasman W, Jaeger EA. *Duane's ophthalmology*; 2011.
33. Chime AA. Ocular manifestations of HIV/AIDS in Enugu State, South Eastern Nigeria. A dissertation submitted to National Postgraduate Medical College of Nigeria for the award of FMCOPh ; 2018.
34. Kim SJ, Park SJ, Yu HG, Kim NJ, Jang HC, Oh MD. Ocular manifestations of acquired immunodeficiency syndrome in Korea. *J Korean Med Sci*. 2012;27(5):542-6. DOI: 10.3346/jkms.2012.27.5.542, PMID 22563221.
35. Azonobi IR, Udoye E, Tebepah T, Opubiri IR. Ocular manifestation of HIV / AIDS infection among patients receiving highly active antiretroviral therapy (HAART) in a tertiary eye care centre. *J AIDS HIV Res*. 2013;5(9):322-7.
36. Adepoju FG, Olawumi HO, Adekoya BJ. HIV seropositivity and related eye diseases in UIITH Ilorin. *Niger Postgrad Med J*. 2007;14(2):163-5. PMID 17599118.
37. Osahon AI, Onunu AN. Ocular disorders in patients infected with the human immunodeficiency virus at the University of Benin Teaching Hospital, Benin City, Nigeria. *Niger J Clin Pract*. 2007;10(4): 283-6. PMID 18293635.
38. Sharew G, Azage M. Predictors of HIV / AIDS related ocular manifestations among HIV / AIDS patients in Felege Hiwot referral Hospital, Northwest Ethiopia. *J Ophthalmol*. 2015;2015:965627. DOI: 10.1155/2015/965627, PMID 26000175.
39. Cochereau I, Mlika-cabanne N, Godinaud P, Niyongabo T, Poste B, Ngayiragije A et al. AIDS related eye disease in Burundi, Africa. *Br J Ophthalmol*. 1999;83(3): 339-42. DOI: 10.1136/bjo.83.3.339, PMID 10365044.
40. Omolase C, Komolafe O, Ayodeji O, Omolase B, Akinwalere AK, Majekodunmi MY. Ocular manifestations in HIV-AIDS patients in a Nigerian community. *S Afr Fam Pract*. 2012;54(5):455-8. DOI: 10.1080/20786204.2012.10874270.

© 2022 Chime et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<https://www.sdiarticle5.com/review-history/92431>